Moving in the opposite direction earlier this year and citing cost constraints, the state health plan in North Carolina restricted coverage of GLP-1s to members with particular health conditionsand weight loss would no longer qualify
Until that completes and regulators review it, retatrutide remains investigational, with no marketing authorization, no licensed supply, and no approved labeling defining who it is for or how it should be used
Because appetite suppression ends, but metabolic inefficiencies remain uncorrected
Weight loss from Semaglutide GLP-1 may not be permanent without ongoing lifestyle modifications and support, but with appropriate strategies, it is possible to sustain weight loss after discontinuing Semaglutide GLP-1 treatment
Patients should be aware that persistent vomiting or diarrhoea can lead to dehydration , and adequate fluid intake is important